-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30

Benzinga·08/17/2026 11:27:15
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.